Jennewein Biotechnologie

News and Press Announcements


25.11.2019 Jennewein Biotechnologie sues Glycom for patent infringement in Denmark

Jennewein Biotechnologie develops fermentative processes for manufacturing of human milk oligosaccharides (HMOs) cost efficiently in an industrial scale since 2005 to make these special sugars available for affordably priced infant formula and other uses in food. Jennewein Biotechnologie was the first commercial vendor of HMOs, and brought the HMO 2’-fucosyllactose for the first time on the market in 2015.

The Danish company Glycom A/S initially tried to chemically synthesize HMOs, but now imitates the path of biotechnological manufacturing of HMOs as pursued by Jennewein Biotechnologie from their beginning.

“After Glycom unsuccessfully tried for a decade to realize the chemical synthesis of HMOs at reasonable costs and in industrially relevant amounts, they now imitate Jennewein’s processes and infringe our intellectual property.” said Dr. Stefan Jennewein, CEO of Jennewein Biotechnologie GmbH. “We will enforce our intellectual property rights against Glycom to remain the leading supplier of HMOs.” adds Dr. Andreas Hübel, Director IP of Jennewein Biotechnologie GmbH.

Jennewein Biotechnologie has already obtained a seizure order against Glycom and additional evidence seized which will further substantiate infringement of Jennewein’s European Patent EP 2 896 628 B1, and requested an interlocutory injunction against the manufacturing and offering of certain HMO products in Denmark. “Besides the infringement of said patent, we see a number of additional infringements of our IPRs by Glycom.” said Dr. Andreas Hübel.